TG Therapeutics (TGTX) drew fresh attention after unveiling early Phase 1 data for azercabtagene zapreleucel in progressive multiple sclerosis, along with progress updates on subcutaneous BRIUMVI and its fully enrolled Phase 3 program.
Those clinical updates dropped into a period where TG Therapeutics has already been on a strong run, with a year to date share price return of 98.36% and a 3 year total shareholder return of about 4.3x. The latest 7 day share price gain of 7.22% and 90 day share price return of 11.63% suggest momentum is still building around the story at a current share price of US$58.08.
Scan other fast-moving MS and biotech stories by comparing TG Therapeutics with 36 healthcare AI stocks that are already drawing attention from the market.
The recent surge in TG Therapeutics could reflect investors reassessing the underlying MS franchise as much as chasing fresh headlines. Is the current price still aligned with the fundamentals on offer?
Most Popular Narrative: 16.7% Undervalued
Against the last close at $58.08, the most followed narrative anchors TG Therapeutics to a fair value of $69.71, which frames the recent surge as still leaving a valuation gap on the table.
The planned launch of subcutaneous BRIUMVI remains a key upcoming catalyst, as it targets the 35 to 40% of the anti CD20 multiple sclerosis market that is currently in self administered products where TG Therapeutics does not yet participate. This could materially affect future revenue and earnings.
The fully enrolled Phase 3 program for subcutaneous BRIUMVI is supported by Phase 1 data indicating around 60% bioavailability and acceptable injection tolerability and is guided toward a potential 2028 launch. This could allow TG Therapeutics to participate in both infusion and self administered anti CD20 segments and affect top line growth and operating leverage.
See why 73 investors see TG Therapeutics as 17% undervalued.
Result: Fair Value of $69.71 (UNDERVALUED)
Still, the TG Therapeutics story can change quickly if BRIUMVI cost pressures persist or if the fiduciary duty investigation escalates and diverts management’s focus.
Find out about the key risks to this TG Therapeutics narrative.
Next Steps
If the mixed sentiment around TG Therapeutics has you undecided, consider reviewing the numbers promptly, weighing both sides, and examining the 4 key rewards and 1 important warning sign.
Looking for more TG Therapeutics sized ideas?
If TG Therapeutics has sharpened your focus, do not stop here. Broaden your watchlist with a few targeted stock ideas sourced directly from the Simply Wall Street Screener.
- Target potential bargains by scanning a curated set of 30 high quality undervalued stocks that pair quality fundamentals with pricing that may not yet reflect their full potential.
- Strengthen your income stream by reviewing 7 dividend fortresses that combine higher yields with businesses built around recurring cash flows.
- Reduce portfolio stress by zeroing in on 30 resilient stocks with low risk scores that score well on financial resilience and business stability.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com